The Blood Centers of America (BCA) and Covance announce the renewal of their agreement to work together to advance the development of cell and gene therapies. As part of the agreement, the companies will continue to collaborate and provide sponsors easier access to development solutions, including access to research- and clinical-grade products and manufacturing.
In addition to Covance capabilities spanning the entire development and post-approval continuum, the agreement facilitates sponsors access to:
The agreement reflects both organizations’ commitment to advancing the development of precision medicines. For Covance, the agreement expands upon its global expertise, capabilities and investment in the development of cell and gene therapies to help sponsors de-risk the development of precision medicines and bring therapies to patients sooner.
For more information about the Blood Centers of America, please visit https://bca.coop/.